عنوان

Melanoma :

شابک

128082123X

شابک

1468496689

شابک

1592591590

شابک

6610821232

شابک

9781280821233

شابک

9781468496680

شابک

9781592591596

شابک

9786610821235

شماره

b730327

عنوان اصلي

Melanoma :

نام عام مواد

[Book]

ساير اطلاعات عنواني

Biologically Targeted Therapeutics /

نام نخستين پديدآور

edited by Ernest C. Borden.

محل نشرو پخش و غیره

Totowa, N.J. :

محل نشرو پخش و غیره

Totowa, NJ :

نام ناشر، پخش کننده و غيره

Humana Press,

نام ناشر، پخش کننده و غيره

Humana Press,

تاریخ نشرو بخش و غیره

©2002.

تاریخ نشرو بخش و غیره

2002.

نام خاص و کميت اثر

1 online resource (415 pages)

عنوان فروست

Current Clinical Oncology

متن يادداشت

Includes bibliographical references and index.

متن يادداشت

I Perspective on the Clinical Disease -- 1 Management of Primary Malignant Melanoma -- 2 A Pathologist's Perspective on Prognostic Featuresof Malignant Melanoma -- 3 Clinical Prognostic Factors and Staging -- II Biological and Targeted Therapeutics -- 4 Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression -- 5 Immunotherapy of Advanced Melanoma Directed at Specific Antigens -- 6 Melanoma Antigens: Vaccines and Monoclonal Antibodies -- 7 Interleukin-2 -- 8 Interleukin-12: Immunologic and Antitumor Effects in Human Malignant Melanoma -- 9 Interferons: Preclinical and Clinical Studies in Melanoma -- 10 Biochemotherapy of Melanoma -- 11 Signal Transduction Abnormalities as Therapeutic Targets -- 12 Tumor Angiogenesis -- 13 Antiangiogenic Therapy for Melanoma.

بدون عنوان

0

متن يادداشت

Substantial progress in the effective prevention and treatment of primary and recurrent melanomas is now being regularly achieved using therapeutic proteins and cells. In Melanoma: Biologically Targeted Therapeutics, Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of these biologicals. Throughout, the focus is on providing the rationale and background by which the many promising biologically targeted therapies are translated via clinical trials into effective new therapies. Among the interventional agents treated are cytokines, monoclonal antibodies, targeted inhibitors, cellular therapies, and angiogenesis inhibitors. Special attention is given to adjuvant therapies for melanoma in patients staged as being at high risk for recurrence. These therapies include interferons, vaccines aimed at stimulating T cell response, and therapies targeted at abnormal melanoma cell proliferative signaling and angiogenesis inhibitors. Among the cutting-edge therapies discussed are novel cytokines that influence dendritic NK and T cell function, an allogenic cellular extract vaccine, and new targets (NF-kB and IL-8) for antiangiogenesis therapies. State-of-the-art and forward looking, Melanoma: Biologically Targeted Therapeutics critically evaluates the biological, cellular, and targeted therapies that are already reducing mortality from primary melanomas, and are expected increasingly to continue so for the foreseeable future.

شماره استاندارد بين المللي کتاب و موسيقي

0896038769

موضوع مستند نشده

Biological products-- Therapeutic use.

موضوع مستند نشده

Medicine.

موضوع مستند نشده

Melanoma-- Immunotherapy.

موضوع مستند نشده

Oncology.

موضوع مستند نشده

Proteins-- Therapeutic use.

موضوع مستند نشده

Biological products-- Therapeutic use.

موضوع مستند نشده

Medicine.

موضوع مستند نشده

Oncology.

موضوع مستند نشده

Proteins-- Therapeutic use.

موضوع مستند نشده

MED062000

موضوع مستند نشده

MJCL

شماره

شماره رده

مستند نام اشخاص تاييد نشده

Borden, Ernest C.

مستند نام اشخاص تاييد نشده

Borden, Ernest C.

تاريخ عمليات

20201216041157.0

نام الکترونيکي

نوع ماده

[Book]

تكميل شده

Y